NEW YORK, Nov. 24, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

jwplayer.key=”3Fznr2BGJZtpwZmA+81lm048ks6+0NjLXyDdsO2YkfE=”   NYSE Content Advisory: Pre-Market Update + Exzeo Celebrates Recent IPO jwplayer(‘myplayer1’).setup({file: ‘https://mma.prnasia.com/media2/2830924/NYSE_Market_Update_16_9_Nov_24.mp4’, image: ‘https://mma.prnasia.com/media2/2830924/NYSE_Market_Update_16_9_Nov_24.mp4?p=thumbnail’, autostart:’false’, stretching : ‘uniform’, width: ‘512’, height: ‘288’});

Ashley Mastronardi delivers the pre-market update on November 24th

Stocks open higher Monday as Wall Street begins a holiday-shortened trading week, following Friday’s rally where the S&P 500 rose about 1% and the Dow gained nearly 500 points. Rate cut expectations grow after NY Fed President John Williams signaled "further adjustment" to interest rates; traders largely anticipate a 25-basis-point cut at the Fed’s December 10 policy meeting. September Producer Price Index and U.S. retail sales reports due Tuesday; meanwhile, Exzeo celebrates its IPO by ringing the NYSE opening bell, with CEO Paresh Patel featured on the podium.

Opening BellExzeo (NYSE: XZO) celebrates its initial public offering

Closing BellMitsubishi UFJ Financial Group (NYSE: MUFG) celebrates the 20th anniversary of founding

Click here to download the NYSE TV App

Video – https://mma.prnasia.com/media2/2830924/NYSE_Market_Update_16_9_Nov_24.mp4

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

Case Report of Mabwell's Nectin-4 targeting ADC (9MW2821) in Cervical Cancer Published in The New England Journal of Medicine

SHANGHAI, April 22, 2026 /PRNewswire/ — Mabwell (688062.SH), an innovation-driven biopharmaceutical company…

Singlomics Announces First Patient Dosed in Phase I Clinical Trial of DXP-106 (IL-1RAP mAb) in China

BEIJING, April 7, 2026 /PRNewswire/ — Singlomics Biopharmaceuticals, an innovative clinical-stage biopharmaceutical…

Well-grounded Confidence! How China's domestic growth drivers propel a strong start to its 15th Five-Year Plan

BEIJING, Feb. 28, 2026 /PRNewswire/ — A news report from China.org.cn on Chinese…